Robert L. Dow

3.7k total citations · 1 hit paper
48 papers, 2.9k citations indexed

About

Robert L. Dow is a scholar working on Organic Chemistry, Molecular Biology and Pharmacology. According to data from OpenAlex, Robert L. Dow has authored 48 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Organic Chemistry, 13 papers in Molecular Biology and 10 papers in Pharmacology. Recurrent topics in Robert L. Dow's work include Cannabis and Cannabinoid Research (6 papers), Neurotransmitter Receptor Influence on Behavior (5 papers) and Marine and fisheries research (5 papers). Robert L. Dow is often cited by papers focused on Cannabis and Cannabinoid Research (6 papers), Neurotransmitter Receptor Influence on Behavior (5 papers) and Marine and fisheries research (5 papers). Robert L. Dow collaborates with scholars based in United States and China. Robert L. Dow's co-authors include Joseph P. Gardner, William H. Brissette, Paul S. Changelian, Brian A. Pollok, Patricia A. Connelly, Elora J. Weringer, Jeffrey H. Hanke, David A. Evans, James M. Takacs and Thomas L. Shih and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Biochemical and Biophysical Research Communications.

In The Last Decade

Robert L. Dow

47 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor

1996 1.8k citations Jeffrey H. Hanke, Joseph P. Gardner et al. Journal of Biological Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert L. Dow United States	19	1.4k	672	406	392	309	48	2.9k
William J. Pitts United States	20	2.4k 1.7×	965 1.4×	673 1.7×	543 1.4×	385 1.2×	34	4.4k
Xin-Yun Huang United States	24	2.2k 1.5×	335 0.5×	480 1.2×	468 1.2×	499 1.6×	27	3.4k
Eugene R. DeSombre United States	33	1.9k 1.3×	302 0.4×	767 1.9×	630 1.6×	197 0.6×	87	5.2k
William T. Schrader United States	44	3.2k 2.3×	287 0.4×	457 1.1×	729 1.9×	449 1.5×	96	6.3k
Hilary McLauchlan United Kingdom	13	3.2k 2.2×	303 0.5×	775 1.9×	431 1.1×	537 1.7×	16	4.6k
Akira Takai Japan	25	2.7k 1.9×	258 0.4×	154 0.4×	239 0.6×	633 2.0×	70	4.1k
Hiroshi Shima Japan	35	3.0k 2.1×	185 0.3×	599 1.5×	388 1.0×	187 0.6×	141	4.0k
Steve Arkinstall United States	25	3.4k 2.4×	204 0.3×	496 1.2×	557 1.4×	501 1.6×	34	4.3k
Heung‐Chin Cheng Australia	29	2.3k 1.6×	132 0.2×	359 0.9×	241 0.6×	464 1.5×	71	3.0k
Steven M. Seiler United States	29	1.4k 1.0×	491 0.7×	138 0.3×	113 0.3×	400 1.3×	71	2.6k

Countries citing papers authored by Robert L. Dow

Since Specialization

Citations

This map shows the geographic impact of Robert L. Dow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Dow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Dow more than expected).

Fields of papers citing papers by Robert L. Dow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert L. Dow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Dow. The network helps show where Robert L. Dow may publish in the future.

Co-authorship network of co-authors of Robert L. Dow

This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. Dow. A scholar is included among the top collaborators of Robert L. Dow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert L. Dow. Robert L. Dow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chirapu, Srinivas Reddy, Charles J. Rotter, Emily Miller, et al.. (2013). High Specificity in Response of the Sodium-Dependent Multivitamin Transporter to Derivatives of Pantothenic Acid. Current Topics in Medicinal Chemistry. 13(7). 837–842. 10 indexed citations

Dow, Robert L., Jiancheng Li, E. Michael Gibbs, et al.. (2013). Defining the key pharmacophore elements of PF-04620110: Discovery of a potent, orally-active, neutral DGAT-1 inhibitor. Bioorganic & Medicinal Chemistry. 21(17). 5081–5097. 17 indexed citations

Tu, Meihua, Alan M. Mathiowetz, Jeffrey A. Pfefferkorn, et al.. (2013). Medicinal Chemistry Design Principles for Liver Targeting Through OATP Transporters. Current Topics in Medicinal Chemistry. 13(7). 857–866. 38 indexed citations

Dow, Robert L., Gary E. Aspnes, E. Michael Gibbs, et al.. (2011). Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core. Bioorganic & Medicinal Chemistry Letters. 21(20). 6122–6125. 12 indexed citations

Dow, Robert L., Jiancheng Li, E. Michael Gibbs, et al.. (2011). Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1. ACS Medicinal Chemistry Letters. 2(5). 407–412. 70 indexed citations

Hadcock, John R., Philip A. Carpino, Philip A. Iredale, et al.. (2010). Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) Receptor Antagonist. BMC Pharmacology. 10(1). 9–9. 12 indexed citations

Dow, Robert L., John R. Hadcock, Dennis O. Scott, et al.. (2009). Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: Potent, orally-active 1,4-disubstituted imidazoles. Bioorganic & Medicinal Chemistry Letters. 19(18). 5351–5354. 11 indexed citations

Li, Jie Jack, Lorna H. Mitchell, & Robert L. Dow. (2009). Thyroid receptor agonists for the treatment of androgenetic alopecia. Bioorganic & Medicinal Chemistry Letters. 20(1). 306–308. 15 indexed citations

Dow, Robert L., Ernest S. Paight, John R. Hadcock, et al.. (2004). Potent and selective, sulfamide-based human β3-adrenergic receptor agonists. Bioorganic & Medicinal Chemistry Letters. 14(12). 3235–3240. 13 indexed citations

10.

Dow, Robert L.. (1997). β3-adrenergic agonists: potential therapeutics for obesity. Expert Opinion on Investigational Drugs. 6(12). 1811–1825. 40 indexed citations

11.

Hanke, Jeffrey H., Joseph P. Gardner, Robert L. Dow, et al.. (1996). Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor. Journal of Biological Chemistry. 271(2). 695–701. 1773 indexed citations breakdown →

12.

Dow, Robert L., Thomas T. Chou, Bruce M. Bechle, C Goddard, & Eric R. Larson. (1994). Identification of Tricyclic Analogs Related to Ellagic Acid as Potent/Selective Tyrosine Protein Kinase Inhibitors. Journal of Medicinal Chemistry. 37(14). 2224–2231. 36 indexed citations

13.

Dow, Robert L., Thomas T. Chou, Bruce M. Bechle, C Goddard, & Eric R. Larson. (1994). ChemInform Abstract: Identification of Tricyclic Analogues Related to Ellagic Acid as Potent/Selective Tyrosine Protein Kinase Inhibitors.. ChemInform. 25(48). 3 indexed citations

14.

Dow, Robert L. & David A. Clark. (1992). Overview: Diabetes: New Chemical Entities. 2(4). 349–363. 5 indexed citations

15.

Dow, Robert L., Bruce M. Bechle, Thomas T. Chou, et al.. (1991). Benzyloxazolidine-2,4-diones as potent hypoglycemic agents. Journal of Medicinal Chemistry. 34(5). 1538–1544. 52 indexed citations

16.

Evans, David A., Robert L. Dow, Thomas L. Shih, James M. Takacs, & Robert Zahler. (1990). Total synthesis of the polyether antibiotic ionomycin. Journal of the American Chemical Society. 112(13). 5290–5313. 181 indexed citations

17.

Dow, Robert L.. (1990). An efficient synthesis of ethyl 5-oxazoleacetates. The Journal of Organic Chemistry. 55(1). 386–388. 21 indexed citations

18.

Dow, Robert L., et al.. (1987). Total synthesis of erbstatin.. Tetrahedron Letters. 28(20). 2217–2220. 3 indexed citations

19.

Evans, David A., Eric B. Sjogren, Javier Bartrolí, & Robert L. Dow. (1986). Aldol addition reactions of chiral crotonate imides. Tetrahedron Letters. 27(41). 4957–4960. 95 indexed citations

20.

Doyle, Michael P. & Robert L. Dow. (1980). Selective Oxidations of Alcohols by Bromine in Combination with Nickel(II) Benzoate. Synthetic Communications. 10(11). 881–888. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact